🧬 AI-Powered Drug Discovery

Sentinus.AI®

Transforming Drug Discovery for Cancer Therapeutics, CNS Disorders, Autoimmune Diseases, Metabolic Diseases, Companion Diagnostics & Infectious Disease

A boosted virtual B cell with the capacity to screen 10 billion antibody sequences and select your best options (affinity, toxicity, efficacy) in hours, not months.

Schedule a Demo Explore Products
10,000×
More Efficient
vs. Google AlphaFold AI
80%
Lower Cost
vs. traditional methods
40%
Wet-Lab Hit Rate
vs. industry avg. 2–5%
$350B+
Market Opportunity
therapeutics + CDx
How It Works

AI-Powered Drug Discovery Pipeline

From target identification to validated candidates in weeks, not years

🎯

Target Identification

AI screens entire proteome to identify optimal drug targets

→
🧬

Antibody Design

Screen 10 billion sequences computationally in hours

→
🔬

In Silico Validation

Predict binding affinity, toxicity, and efficacy

→
✅

Wet-Lab Confirmation

40% hit rate vs. industry 2-5%

Our Expertise

Targeting Complex Biological Pathways

Microscopic Cancer Cells

Cancer Therapeutics

Targeting tumor-specific antigens with precision-designed antibodies

T-Cell Immunotherapy

Immuno-Oncology

Modulating immune checkpoints for enhanced anti-tumor response

Coronavirus Pathogen

Infectious Disease

Rapid antibody design for emerging pathogens and pandemic response

Cellular Metabolism

Metabolic Diseases

Novel biologics targeting metabolic pathways for diabetes, obesity, and related conditions

Brain Neurons CNS

CNS Disorders

Precision antibodies crossing the blood-brain barrier for neurological conditions including Alzheimer's, Parkinson's, and ALS

Immune Cells Autoimmune

Autoimmune Diseases

Targeted immunomodulators for rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease

Recognition

Awards & Publications

🏆

Merck Pandemic Preparedness Award

Recognized for breakthrough work in rapid antibody design for emerging infectious diseases.

🔬

Gates Foundation Heritage

Core technology developed through global health initiatives tackling infectious disease.

📄

Nature Scientific Reports

Peer-reviewed publication with independent validation of our AI-designed antibody results.

Read Paper →
Trusted By

Leading Organizations

60+
Validated Projects
20+
Fee-for-Service Contracts
100+
Pipeline Engagements

Ready to Transform Drug Discovery?

Join Pfizer, Bayer, Yale, and 60+ organizations using Sentinus.AI

Contact Us Today